Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
Posted on: Monday, 26 January 2009, 07:00 CST
RapidArc delivers a precise and efficient treatment in a single or multiple arcs of the treatment machine around the patient and makes it possible to deliver advanced image-guided intensity modulated radiotherapy (IMRT) two to eight times faster than is possible with conventional IMRT. At Sudharz Krankenhaus Nordhausen, doctors have been able to reduce the treatment time to just two and a half minutes compared with up to 30 minutes for complex IMRT treatments.
"It is very gratifying for me to begin treatments using the most modern
moving arc method of radiotherapy," says Dr.
Dr. Oehler said RapidArc was a valuable weapon in the hospital's goal of bringing down waiting lists. "We knew we needed a brilliant new method of shortening treatment times and avoiding waiting lists while improving the quality of the treatment and it was not a hard decision to select RapidArc," he added.
Sudharz Krankenhaus treats up to 900 patients a year using two Varian
Clinac(R) medical linear accelerators. The hospital pioneered advanced IMRT
treatments in
The hospital's work has been praised by the president of the German Cancer
Aid Society, Prof. Dr.
With RapidArc, Varian's Clinac accelerator can target radiation beams at a tumor while continuously rotating around the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers because they target tumors using a complex sequence of fixed beams from multiple angles.
Editorial contact:
About Varian Medical Systems
Varian Medical Systems, Inc., of
SOURCE Varian Medical Systems, Inc.
Source: PR Newswire
Related Articles
- Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Krames Announces Agreement With Montefiore Medical Center to Implement Web-Based Patient Education System
- Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients
- New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
- Thai Cabinet Approves Budget for Treatment of Botulism Patients
- China Provides Free Treatment to TB Patients
- New Planning Tool Streamlines Brachytherapy Treatments and Improves Patient Comfort
- TB Patients Have Access to Treatment in China's Less-Developedrural Areas
User Comments (0)

RSS Feeds